Case Number:

IPR2022-00712

Case Type:

IPR

Status:

Terminated-Denied

Petitioner:

Wuhan Healthgen Biotechnology Corp. of Wuhan, China

1. Filed: March 17, 2022 00:00

   Coverage

   1. August 22, 2022

      PTAB Denies Chinese Co.'s IPR Targeting Cultured Cell Patent

      The Patent Trial and Appeal Board has declined to institute inter partes review of a Ventria Biosciences Inc. patent on cell culture media in a challenge brought by Wuhan Healthgen Biotechnology Corp., saying the petition wasn't likely to succeed.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login